Hodgkin Lymphoma
Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Loretta Nastoupil, MDVideo Insights | September 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Blood Cancers Today Staff WritersHodgkin Lymphoma | August 28, 2023
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Cailin ConnerHodgkin Lymphoma | August 8, 2023
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
Blood Cancer TalksBlood Cancer Talks | July 19, 2023
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Cecilia BrownPrint | July 19, 2023
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Advertisement
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Leah SherwoodHodgkin Lymphoma | July 10, 2023
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
Leah SherwoodMeeting News | June 26, 2023
Multiple regression did not define any independent predictor of response for early evaluation among the baseline parameters.
Cecilia BrownHodgkin Lymphoma | June 8, 2023
Most patients were able to avoid escBEACOPP plus radiotherapy based on PET results.
Chadi Nabhan, MD, MBA, FACPMeeting News | June 7, 2023
The study compared nivolumab plus AVD with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | June 6, 2023
The study showed that nivolumab plus AVD improved PFS over brentuximab vedotin plus AVD.
Cecilia BrownMeeting News | April 20, 2023
BV-AVEPC showed “consistent efficacy” in pediatric patients across age groups “despite lower exposure."
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 9, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Cecilia BrownHodgkin Lymphoma | January 5, 2023
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodHodgkin Lymphoma | November 21, 2022
The FDA approved brentuximab vedotin for pediatric patients with previously untreated high-risk classic Hodgkin lymphoma.
Leah SherwoodHodgkin Lymphoma | November 15, 2022
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
Leah LawrenceHodgkin Lymphoma | May 10, 2022
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Advertisement
Advertisement
Editorial Board